MetaCap

Verrica Pharmaceuticals Inc. (VRCA)

NASDAQ: VRCAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.74-0.145 (-5.03%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

VRCA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$47.07M
EPS (TTM)
-$2.30
52-week range
2.73 – 9.82
Day range
2.73 – 2.96
Volume / Avg
127.03K / 68.78K
Beta
—

52-week range

$2.73$9.82

VRCA stock today

On Nov 20, VRCA ended the session at $2.74, shedding $0.145 (5.03%), versus the S&P 500's 3.70% decline. At this level, VRCA sits near the bottom of its 52-week range of $2.73 to $9.82: 72.1% below the high, set on Nov 28, 2025 and 0.4% above the low. VRCA is down 67.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 34.9%.

Verrica Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$2.30), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Verrica Pharmaceuticals

Company profile

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Jayson M. Rieger M.B.A., Ph.D.
Headquarters
West Chester, PA
Employees
76
IPO year
2018

Financial highlights

Full financials

In fiscal 2025, Verrica Pharmaceuticals generated $35.6 million in revenue, up 370.2% from fiscal 2024, its 2nd consecutive year of revenue growth. Verrica Pharmaceuticals reported a net loss of $17.9 million, compared with a loss of $76.6 million a year earlier. Operating margin was -34.2%.

Verrica Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$35.58M$7.57M$5.12M$9.03M$12.00M
Growth+370.22%+47.66%-43.27%-24.73%—
Net income$-17.89M$-76.58M$-67.00M$-24.49M$-35.08M
EPS (diluted)$-1.68$-14.78$-1.48$-0.72$-1.30

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$13.83+404.74%

  • Strong buy 0
  • Buy 6
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $9.00High $20.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$0.05 vs $-0.50
Surprise
+110.00%

VRCA news

All VRCA news

Verrica Pharmaceuticals peers

Health Care sector
VRCA peer companies
CompanyPrice% ChgMarket capCompare
NMADNomad Power Solutions Inc.2.56+13.53%$47.15Mvs VRCA
ONCYOncolytics Biotech Inc.0.3501-10.37%$47.66Mvs VRCA
TNXPTonix Pharmaceuticals Holding Corp.2.38-6.67%$46.25Mvs VRCA
MISTMilestone Pharmaceuticals Inc.0.3711-7.06%$46.20Mvs VRCA
RFLRafael Holdings Inc. Class B0.9197+2.19%$47.99Mvs VRCA
HRTXHeron Therapeutics Inc.0.2525-4.39%$48.04Mvs VRCA
HOWLWerewolf Therapeutics Inc.0.9466-3.97%$46.00Mvs VRCA
RNXTRenovoRx Inc.0.942-10.29%$45.45Mvs VRCA

Indexes, lists and sector

Verrica Pharmaceuticals stock FAQ

What is Verrica Pharmaceuticals's stock price today?

VRCA last traded at $2.74 as of Nov 20, 4:00 PM EST, down 5.03% on the day. Prices are delayed at least 15 minutes.

Does Verrica Pharmaceuticals pay a dividend?

No. Verrica Pharmaceuticals does not currently pay a regular cash dividend.

Who is Verrica Pharmaceuticals's CEO?

Dr. Jayson M. Rieger M.B.A., Ph.D. is the chief executive officer of Verrica Pharmaceuticals Inc., which has about 76 employees.

Has VRCA ever split its stock?

Yes. The most recent VRCA stock split was a 1-for-10 split on Jul 25, 2025.

What is the VRCA 52-week high?

The 52-week high for VRCA is $9.82 and the 52-week low is $2.73. The stock is currently 72.1% below its high.

Compare VRCA